Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Dr. Nitin Telang

Dr. Nitin Telang

Palindrome Liaisons Consultants, New Jersy, USA

Title: Breast Cancer Stem Cell Models for Therapeutic Alternatives

Biography

Biography: Dr. Nitin Telang

Abstract

Rationale: Progression of breast cancer to advanced stage metastatic disease represents a major cause of mortality in women. Therapeutic options of conventional chemo-endocrine and molecularly targeted interventions are associated with spontaneous or acquired resistance and emergence of chemo-resistant cancer initiating premalignant stem cell population. These limitations emphasize development of reliable stem cell models for identifying testable therapeutic alternatives.

Research Outcome: Drug-resistant stem cell models relevant to select clinical breast cancer subtypes exhibit progressive growth and increased tumour spheroid formation in response to cytotoxic concentrations of mechanistically distinct small molecule inhibitors Tamoxifen (TAM), Lapatinib (LAP) and Doxorubicin (DOX). The drug-resistant TAM-R, LAP-R and DOX-R phenotypes exhibit unregulated expressions of cell surface protein CD44 and nuclear transcription factors NANOG and OCT-4. Treatment of LAP-R stem cell model with naturally-occurring vitamin A derivative all-trans retinoic acid (ATRA) and terpene carnosol (CSOL) inhibit tumour spheroid formation and down regulate the expressions of CD44, NANOG and OCT-4.

Conclusions: Development and characterization of drug-resistant stem cell models and inhibitory efficacy of natural products validate a novel mechanism-based experimental approach. This approach may facilitate prioritization of efficacious pharmacological agents, dietary phytochemicals and bioactive compounds from nutritional herbs as testable alternatives against therapy-resistant breast cancer.